Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats

N. Matsukawa, M. Maki, T. Yasuhara, K. Hara, G. Yu, L. Xu, K. M. Kim, J. C. Morgan, K. D. Sethi, C. V. Borlongan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD). Based on recent studies implicating dopamine receptors 2 and 3 (D2R and D3R) as possible targets of ropinirole, we over-expressed these dopamine receptor genes in the dopamine-denervated striatum of rodents to reveal whether their over-expression modulated ropinirole activity. Adult Sprague-Dawley rats initially received unilateral 6-hydroxydopamine lesion of the medial forebrain bundle. At 1 month after surgery, successfully lesioned animals (3 or less forelimb akinesia score, and 8 or more apomorphine-induced rotations/min over 1 h) were randomly assigned to intrastriatal injection (ipsilateral to the lesion) of blank lentiviral vector, D2R, D3R or both genes. At about 5 months post-lesion, ropinirole (0.2 mg/kg, i.p.) was administered daily for 9 consecutive days. The subtherapeutic dose of ropinirole improved the use of previously akinetic forelimb and produced robust circling behavior in lesioned animals with striatal over-expression of both D2R and D3R compared to lesioned animals that received blank vector. In contrast, the subtherapeutic dose of ropinirole generated only modest motor effects in lesioned animals with sole over-expression of D2R or D3R. Western immunoblot and autoradiographic assays showed enhanced D2R and D3R protein levels coupled with normalized D2R and D3R binding in the ventral striatum of lesioned animals with lentiviral over-expression of both D2R and D3R relative to vehicle-treated lesioned animals. Immunohistochemical analyses showed that D2R and D3R GFP fluorescent cells colocalized with enkephalin and substance P immunoreactive medium spiny neurons. These data support the use of the subtherapeutic dose of ropinirole in a chronic model of PD.

Original languageEnglish (US)
Pages (from-to)113-123
Number of pages11
JournalBrain Research
Volume1160
Issue number1
DOIs
StatePublished - Jul 30 2007

Fingerprint

Oxidopamine
Forelimb
Dopamine Receptors
Parkinson Disease
Medial Forebrain Bundle
Corpus Striatum
Apomorphine
Enkephalins
Dopamine Agonists
Substance P
ropinirole
Genes
Sprague Dawley Rats
Rodentia
Dopamine
Western Blotting
Neurons
Injections
Proteins

Keywords

  • Dopamine receptor agonist
  • Gene therapy
  • Neurodegeneration
  • Striatum

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. / Matsukawa, N.; Maki, M.; Yasuhara, T.; Hara, K.; Yu, G.; Xu, L.; Kim, K. M.; Morgan, J. C.; Sethi, K. D.; Borlongan, C. V.

In: Brain Research, Vol. 1160, No. 1, 30.07.2007, p. 113-123.

Research output: Contribution to journalArticle

Matsukawa, N, Maki, M, Yasuhara, T, Hara, K, Yu, G, Xu, L, Kim, KM, Morgan, JC, Sethi, KD & Borlongan, CV 2007, 'Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats', Brain Research, vol. 1160, no. 1, pp. 113-123. https://doi.org/10.1016/j.brainres.2007.05.030
Matsukawa, N. ; Maki, M. ; Yasuhara, T. ; Hara, K. ; Yu, G. ; Xu, L. ; Kim, K. M. ; Morgan, J. C. ; Sethi, K. D. ; Borlongan, C. V. / Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. In: Brain Research. 2007 ; Vol. 1160, No. 1. pp. 113-123.
@article{a4cf3ae484ef453dacaf4ed1459579fb,
title = "Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats",
abstract = "Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD). Based on recent studies implicating dopamine receptors 2 and 3 (D2R and D3R) as possible targets of ropinirole, we over-expressed these dopamine receptor genes in the dopamine-denervated striatum of rodents to reveal whether their over-expression modulated ropinirole activity. Adult Sprague-Dawley rats initially received unilateral 6-hydroxydopamine lesion of the medial forebrain bundle. At 1 month after surgery, successfully lesioned animals (3 or less forelimb akinesia score, and 8 or more apomorphine-induced rotations/min over 1 h) were randomly assigned to intrastriatal injection (ipsilateral to the lesion) of blank lentiviral vector, D2R, D3R or both genes. At about 5 months post-lesion, ropinirole (0.2 mg/kg, i.p.) was administered daily for 9 consecutive days. The subtherapeutic dose of ropinirole improved the use of previously akinetic forelimb and produced robust circling behavior in lesioned animals with striatal over-expression of both D2R and D3R compared to lesioned animals that received blank vector. In contrast, the subtherapeutic dose of ropinirole generated only modest motor effects in lesioned animals with sole over-expression of D2R or D3R. Western immunoblot and autoradiographic assays showed enhanced D2R and D3R protein levels coupled with normalized D2R and D3R binding in the ventral striatum of lesioned animals with lentiviral over-expression of both D2R and D3R relative to vehicle-treated lesioned animals. Immunohistochemical analyses showed that D2R and D3R GFP fluorescent cells colocalized with enkephalin and substance P immunoreactive medium spiny neurons. These data support the use of the subtherapeutic dose of ropinirole in a chronic model of PD.",
keywords = "Dopamine receptor agonist, Gene therapy, Neurodegeneration, Striatum",
author = "N. Matsukawa and M. Maki and T. Yasuhara and K. Hara and G. Yu and L. Xu and Kim, {K. M.} and Morgan, {J. C.} and Sethi, {K. D.} and Borlongan, {C. V.}",
year = "2007",
month = "7",
day = "30",
doi = "10.1016/j.brainres.2007.05.030",
language = "English (US)",
volume = "1160",
pages = "113--123",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats

AU - Matsukawa, N.

AU - Maki, M.

AU - Yasuhara, T.

AU - Hara, K.

AU - Yu, G.

AU - Xu, L.

AU - Kim, K. M.

AU - Morgan, J. C.

AU - Sethi, K. D.

AU - Borlongan, C. V.

PY - 2007/7/30

Y1 - 2007/7/30

N2 - Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD). Based on recent studies implicating dopamine receptors 2 and 3 (D2R and D3R) as possible targets of ropinirole, we over-expressed these dopamine receptor genes in the dopamine-denervated striatum of rodents to reveal whether their over-expression modulated ropinirole activity. Adult Sprague-Dawley rats initially received unilateral 6-hydroxydopamine lesion of the medial forebrain bundle. At 1 month after surgery, successfully lesioned animals (3 or less forelimb akinesia score, and 8 or more apomorphine-induced rotations/min over 1 h) were randomly assigned to intrastriatal injection (ipsilateral to the lesion) of blank lentiviral vector, D2R, D3R or both genes. At about 5 months post-lesion, ropinirole (0.2 mg/kg, i.p.) was administered daily for 9 consecutive days. The subtherapeutic dose of ropinirole improved the use of previously akinetic forelimb and produced robust circling behavior in lesioned animals with striatal over-expression of both D2R and D3R compared to lesioned animals that received blank vector. In contrast, the subtherapeutic dose of ropinirole generated only modest motor effects in lesioned animals with sole over-expression of D2R or D3R. Western immunoblot and autoradiographic assays showed enhanced D2R and D3R protein levels coupled with normalized D2R and D3R binding in the ventral striatum of lesioned animals with lentiviral over-expression of both D2R and D3R relative to vehicle-treated lesioned animals. Immunohistochemical analyses showed that D2R and D3R GFP fluorescent cells colocalized with enkephalin and substance P immunoreactive medium spiny neurons. These data support the use of the subtherapeutic dose of ropinirole in a chronic model of PD.

AB - Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD). Based on recent studies implicating dopamine receptors 2 and 3 (D2R and D3R) as possible targets of ropinirole, we over-expressed these dopamine receptor genes in the dopamine-denervated striatum of rodents to reveal whether their over-expression modulated ropinirole activity. Adult Sprague-Dawley rats initially received unilateral 6-hydroxydopamine lesion of the medial forebrain bundle. At 1 month after surgery, successfully lesioned animals (3 or less forelimb akinesia score, and 8 or more apomorphine-induced rotations/min over 1 h) were randomly assigned to intrastriatal injection (ipsilateral to the lesion) of blank lentiviral vector, D2R, D3R or both genes. At about 5 months post-lesion, ropinirole (0.2 mg/kg, i.p.) was administered daily for 9 consecutive days. The subtherapeutic dose of ropinirole improved the use of previously akinetic forelimb and produced robust circling behavior in lesioned animals with striatal over-expression of both D2R and D3R compared to lesioned animals that received blank vector. In contrast, the subtherapeutic dose of ropinirole generated only modest motor effects in lesioned animals with sole over-expression of D2R or D3R. Western immunoblot and autoradiographic assays showed enhanced D2R and D3R protein levels coupled with normalized D2R and D3R binding in the ventral striatum of lesioned animals with lentiviral over-expression of both D2R and D3R relative to vehicle-treated lesioned animals. Immunohistochemical analyses showed that D2R and D3R GFP fluorescent cells colocalized with enkephalin and substance P immunoreactive medium spiny neurons. These data support the use of the subtherapeutic dose of ropinirole in a chronic model of PD.

KW - Dopamine receptor agonist

KW - Gene therapy

KW - Neurodegeneration

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=34447336973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447336973&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2007.05.030

DO - 10.1016/j.brainres.2007.05.030

M3 - Article

C2 - 17573046

AN - SCOPUS:34447336973

VL - 1160

SP - 113

EP - 123

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -